| 26.2 -28.78 (-52.35%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 51.53 |
1-year : | 69.74 |
| Resists | First : | 44.12 |
Second : | 59.7 |
| Pivot price | 51.36 |
|||
| Supports | First : | 18.89 |
Second : | 15.72 |
| MAs | MA(5) : | 49.44 |
MA(20) : | 51.54 |
| MA(100) : | 65.23 |
MA(250) : | 73.29 |
|
| MACD | MACD : | -3.1 |
Signal : | -2.1 |
| %K %D | K(14,3) : | 48.3 |
D(3) : | 57.3  |
| RSI | RSI(14): 22.7 |
|||
| 52-week | High : | 123.75 | Low : | 18.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DRUG ] has closed below the lower bollinger band by 40.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ DRUG ] is to continue within current trading range. It is unclear right now based on current values. 74% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 57.03 - 57.32 | 57.32 - 57.55 |
| Low: | 54.18 - 54.48 | 54.48 - 54.71 |
| Close: | 54.51 - 55.01 | 55.01 - 55.39 |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Mon, 02 Nov 2026
Bright Minds Biosciences (NASDAQ:DRUG) Reaches New 12-Month Low - Time to Sell? - MarketBeat
Mon, 02 Nov 2026
Bright Minds stock plunges as FDA halts epilepsy trial - Investing.com
Mon, 02 Nov 2026
Why Did Bright Minds Biosciences Stock (DRUG) Plummet 55% Today? - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 11.4 (%) |
| Held by Institutions | 94.9 (%) |
| Shares Short | 883 (K) |
| Shares Short P.Month | 894 (K) |
| EPS | -2.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -13.5 % |
| Return on Equity (ttm) | -13.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -12.79 |
| PEG Ratio | 0 |
| Price to Book value | 1.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|